Circulating tumor cells and serum tumor biomarkers in small cell lung cancer

Patrick Chi-Chung Ma, Lawrence Blaszkowsky, Ajit Bharti, Andras Ladanyi, Stine Kathrein Kraeft, Adam Bruno, Arthur T. Skarin, Lan Bo Chen, Ravi Salgia

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

Lung cancer accounts for approximately 30% of all cancer mortalities in the United States. Small cell lung cancer (SCLC), which is an aggressive malignancy with frequent and early metastases, accounts for about 15% of all of the lung cancer cases with a dismal 5-year survival rate of <5% with current standard therapies. Early detection of SCLC is challenging, in part due to the lack of adequate serum tumor markers. The goal of this review is to summarize the current knowledge of circulating tumor cells and serum biomarkers in small cell lung cancer. The role of circulating tumor cells in prognostication is controversial, but may be better defined with advancing technologies of detection of such cells with higher precision, and improved clinico-pathological correlations. The current knowledge on the known serum cytokines and tumor biomarkers of SCLC, such as CEA, chromogranin A and neuron-specific enolase will be presented. Serum cytokines, such as vascular endothelial growth factor (VEGF), stem cell factor (SCF) and hepatocyte growth factor/scatter factor (HGF/SF) are also discussed. New findings in the search for novel diagnostic and therapeutic molecular markers using the emerging genomics and proteomics technologies are emphasized. It is our hope that validation of these new research platforms and technologies will result in improved early detection, prognostication and finally treatment of SCLC with potential novel molecularly-targeted therapeutics.

Original languageEnglish (US)
Pages (from-to)49-62
Number of pages14
JournalAnticancer Research
Volume23
Issue number1 A
StatePublished - Jan 1 2003

Fingerprint

Circulating Neoplastic Cells
Small Cell Lung Carcinoma
Tumor Biomarkers
Serum
Hepatocyte Growth Factor
Technology
Lung Neoplasms
Biomarkers
Cytokines
Chromogranin A
Stem Cell Factor
Molecular Pathology
Phosphopyruvate Hydratase
Genomics
Proteomics
Vascular Endothelial Growth Factor A
Neoplasms
Therapeutics
Survival Rate
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Ma, P. C-C., Blaszkowsky, L., Bharti, A., Ladanyi, A., Kraeft, S. K., Bruno, A., ... Salgia, R. (2003). Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Research, 23(1 A), 49-62.
Ma, Patrick Chi-Chung ; Blaszkowsky, Lawrence ; Bharti, Ajit ; Ladanyi, Andras ; Kraeft, Stine Kathrein ; Bruno, Adam ; Skarin, Arthur T. ; Chen, Lan Bo ; Salgia, Ravi. / Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. In: Anticancer Research. 2003 ; Vol. 23, No. 1 A. pp. 49-62.
@article{ef7ce94ddabf4f67bcf6902262c4294c,
title = "Circulating tumor cells and serum tumor biomarkers in small cell lung cancer",
abstract = "Lung cancer accounts for approximately 30{\%} of all cancer mortalities in the United States. Small cell lung cancer (SCLC), which is an aggressive malignancy with frequent and early metastases, accounts for about 15{\%} of all of the lung cancer cases with a dismal 5-year survival rate of <5{\%} with current standard therapies. Early detection of SCLC is challenging, in part due to the lack of adequate serum tumor markers. The goal of this review is to summarize the current knowledge of circulating tumor cells and serum biomarkers in small cell lung cancer. The role of circulating tumor cells in prognostication is controversial, but may be better defined with advancing technologies of detection of such cells with higher precision, and improved clinico-pathological correlations. The current knowledge on the known serum cytokines and tumor biomarkers of SCLC, such as CEA, chromogranin A and neuron-specific enolase will be presented. Serum cytokines, such as vascular endothelial growth factor (VEGF), stem cell factor (SCF) and hepatocyte growth factor/scatter factor (HGF/SF) are also discussed. New findings in the search for novel diagnostic and therapeutic molecular markers using the emerging genomics and proteomics technologies are emphasized. It is our hope that validation of these new research platforms and technologies will result in improved early detection, prognostication and finally treatment of SCLC with potential novel molecularly-targeted therapeutics.",
author = "Ma, {Patrick Chi-Chung} and Lawrence Blaszkowsky and Ajit Bharti and Andras Ladanyi and Kraeft, {Stine Kathrein} and Adam Bruno and Skarin, {Arthur T.} and Chen, {Lan Bo} and Ravi Salgia",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
volume = "23",
pages = "49--62",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 A",

}

Ma, PC-C, Blaszkowsky, L, Bharti, A, Ladanyi, A, Kraeft, SK, Bruno, A, Skarin, AT, Chen, LB & Salgia, R 2003, 'Circulating tumor cells and serum tumor biomarkers in small cell lung cancer', Anticancer Research, vol. 23, no. 1 A, pp. 49-62.

Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. / Ma, Patrick Chi-Chung; Blaszkowsky, Lawrence; Bharti, Ajit; Ladanyi, Andras; Kraeft, Stine Kathrein; Bruno, Adam; Skarin, Arthur T.; Chen, Lan Bo; Salgia, Ravi.

In: Anticancer Research, Vol. 23, No. 1 A, 01.01.2003, p. 49-62.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Circulating tumor cells and serum tumor biomarkers in small cell lung cancer

AU - Ma, Patrick Chi-Chung

AU - Blaszkowsky, Lawrence

AU - Bharti, Ajit

AU - Ladanyi, Andras

AU - Kraeft, Stine Kathrein

AU - Bruno, Adam

AU - Skarin, Arthur T.

AU - Chen, Lan Bo

AU - Salgia, Ravi

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Lung cancer accounts for approximately 30% of all cancer mortalities in the United States. Small cell lung cancer (SCLC), which is an aggressive malignancy with frequent and early metastases, accounts for about 15% of all of the lung cancer cases with a dismal 5-year survival rate of <5% with current standard therapies. Early detection of SCLC is challenging, in part due to the lack of adequate serum tumor markers. The goal of this review is to summarize the current knowledge of circulating tumor cells and serum biomarkers in small cell lung cancer. The role of circulating tumor cells in prognostication is controversial, but may be better defined with advancing technologies of detection of such cells with higher precision, and improved clinico-pathological correlations. The current knowledge on the known serum cytokines and tumor biomarkers of SCLC, such as CEA, chromogranin A and neuron-specific enolase will be presented. Serum cytokines, such as vascular endothelial growth factor (VEGF), stem cell factor (SCF) and hepatocyte growth factor/scatter factor (HGF/SF) are also discussed. New findings in the search for novel diagnostic and therapeutic molecular markers using the emerging genomics and proteomics technologies are emphasized. It is our hope that validation of these new research platforms and technologies will result in improved early detection, prognostication and finally treatment of SCLC with potential novel molecularly-targeted therapeutics.

AB - Lung cancer accounts for approximately 30% of all cancer mortalities in the United States. Small cell lung cancer (SCLC), which is an aggressive malignancy with frequent and early metastases, accounts for about 15% of all of the lung cancer cases with a dismal 5-year survival rate of <5% with current standard therapies. Early detection of SCLC is challenging, in part due to the lack of adequate serum tumor markers. The goal of this review is to summarize the current knowledge of circulating tumor cells and serum biomarkers in small cell lung cancer. The role of circulating tumor cells in prognostication is controversial, but may be better defined with advancing technologies of detection of such cells with higher precision, and improved clinico-pathological correlations. The current knowledge on the known serum cytokines and tumor biomarkers of SCLC, such as CEA, chromogranin A and neuron-specific enolase will be presented. Serum cytokines, such as vascular endothelial growth factor (VEGF), stem cell factor (SCF) and hepatocyte growth factor/scatter factor (HGF/SF) are also discussed. New findings in the search for novel diagnostic and therapeutic molecular markers using the emerging genomics and proteomics technologies are emphasized. It is our hope that validation of these new research platforms and technologies will result in improved early detection, prognostication and finally treatment of SCLC with potential novel molecularly-targeted therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=0345700306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345700306&partnerID=8YFLogxK

M3 - Review article

C2 - 12683352

AN - SCOPUS:0345700306

VL - 23

SP - 49

EP - 62

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 A

ER -

Ma PC-C, Blaszkowsky L, Bharti A, Ladanyi A, Kraeft SK, Bruno A et al. Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Research. 2003 Jan 1;23(1 A):49-62.